Table 2.
Overview of ESM uses in different studies.
| References | Condition | Controls | Device | Prompt design | Duration | Number of daily prompts | Number of items | Compliance | Incentives |
|---|---|---|---|---|---|---|---|---|---|
| Björling & Singh (2017)51 a | Headache | No | Palm pilot M500 | CD, random | 21 days | 7 | 5 | 72% | $75 |
| Borus et al. (2013)36 | Type 1 diabetes | No | Palm Tungsten E2 | Fixed event-contingent | 14 days | 4 | NR | 63% | $100 for >75% compliance |
| Bray et al. (2010)52 | Neuromuscular disorders | No | Palm Z22 | Random signal-contingent | 7 days | 8 | 19 | 79% | NR |
| Bray et al. (2017)53 | Duchenne muscular dystrophy | No | Palm Z22 | Random signal-contingent | 7 days | 8 | 19 | 70% | NR |
| Bromberg et al. (2016)26 | Juvenile idiopathic arthritis | No | Smartphone | Fixed signal-contingent | 1 month | 3 | 9–14 | 66% | Dependent on compliance |
| Bui et al. (2020)70 | Asthma | No | Smartphone + wearable | NR | 1 week | NR | NR | NR | CD |
| Campbell et al. (2006)71 | Asthma | No | Paper & pencil + wearable | Interval-contingent | 13–16 h | 13-16 | NR | NR | NR |
| Connelly et al. (2010)25 | Headache | No | Palm device | Time-contingent | 14 days | 3 | 14 | 84% | Dependent on compliance |
| Connelly & Boorigie (2021)40 | Migraine | No | Smartphone + wearable | Time-contingent | 28 days | 4 | 11–12 | 68.9% | Dependent on compliance |
| Cushing et al. (2019)32 | Abdominal pain | No | Smartphone + wearable | Time-contingent | 14 days | 4 | 45–61 | 76.3% | Dependent on compliance |
| Cushing et al. (2021)72 | Abdominal pain | No | Smartphone | NR | 14 days | 4 | NR | 73% | CD |
| Dougherty et al. (2022)35 | Overweight/obesity | No | Smartphone | Random signal-contingent, interval-contingent & event-contingent | 16 days | 4–6 | 10 | 56% (signal-contingent), 68.6% (interval-contingent) | $100–$150 |
| Dunton et al. (2016)73 | Asthma | No | Smartphone + wearable | Random signal-contingent & event-contingent | 7 days | CD | NR | 50.1% | $100 |
| Egbert et al. (2020)45 | Overweight/ obesity | No | NR | Random signal-contingent, event-contingent & interval-contingent | 15 days | NR | 20 | NR | NR |
| Egbert et al. (2022)47 study 1 | Overweight/ obesity | No | Mobile phone + phone calls | NR | 4 days | 3 | >4 | 74% | NR |
| Egbert et al. (2022)47 study 2 | Overweight/ obesity | No | Palm Pilot PDA | Signal-contingent & event-contingent | 15 days | 3-5 | NR | 69% (signal-contingent) | NR |
| Feller et al. (2021)54 | 22Q11DS | 49 healthy controls | Smartphone | Semi-random signal-contingent | 6 days | 8 | 33-36 | NR | NR |
| Feller et al. (2022)42 | 22Q11DS | 44 healthy controls | Smartphone | Semi-random signal-contingent | 6 days | 8 | 33-38 | NR | €90,- or 100 Fr. |
| Gevonden et al. (2015)57 | Severe hearing impairment | 18 healthy controls | PsyMate | Semi-random signal-contingent | 8 days | 10 | NR | NR | €50,- |
| Ghriwati et al. (2020)27 | Asthma | No | Smartphone + wearable | Fixed signal-contingent | 14 days | 2 | NR | NR | $25-$50 |
| Glista et al. (2021)74 | Hearing aids | No | Asus Zenpad 7 tablet | Event-contingent | 1 week | 2 | NR | 82.4% | CD |
| Goldschmidt et al. (2018)41 | Overweight/ obesity | No | Smartphone | Semi-random signal-contingent, event-contingent & interval-contingent | 15 days | 3-5 | NR | 23.3%-67.6% | $50-$100 |
| Hao et al. (2022)17 | Asthma | No | Smartphone + wearable | Random signal-contingent, interval-contingent & event-contingent | 14 days | NR | NR | NR | NR |
| Heathcote et al. (2022)33 | Childhood cancer survivors | No | Smartphone | Semi-random signal-contingent | 11 days | 3 | NR | 83% | Dependent on compliance |
| Helgeson et al. (2009)18 | Type 1 diabetes | No | Palm pilot + blood glucose meter | Fixed signal-contingent | 4 days | 6-9 | NR | CD | $100 |
| Jessup et al. (2017)28 | Visual impairment | No | Smartphone | Random signal-contingent | 1 week | 7 | NR | 69% | NR |
| Kichline et al. (2019)75 | Chronic abdominal pain | No | Smartphone + wearable | Fixed signal-contingent | 14 days | 4 | 4 | 73% | $40 |
| Kolmodin MacDonell et al. (2016)76 | Asthma | No | Smartphone | Random signal-contingent | 7 days + 7 days | 3 | NR | NR | $200 |
| Kubiak et al. (2018)77 | Obesity | No | Palm Tungsten E2 | Random signal-contingent & event-contingent | 7 days | 4 | NR | CD | CD |
| Lee et al. (2020)43 | Juvenile idiopathic arthritis | No | iPad | NR | 8 weeks | 1-2 | NR | 37.8–63% | NR |
| MacDonell et al. (2012)46 | Asthma | No | Phone | Fixed signal-contingent & event-contingent | 14 days | 1-2 | NR | 78.5% (signal-contingent) | $100 + raffle |
| Miadich et al. (2018)48 | Asthma | No | Smartphone | Fixed signal-contingent | 2 weeks | 2 | 1–6 | CD | NR |
| Mulvaney et al. (2012)56 | Type 1 diabetes | 46 type 1 diabetes, without ESM | Phone calls | Semi-random signal-contingent | 20 days | 2 | 4 | CD | NR |
| Mulvaney et al. (2018)38 | Type 1 diabetes | 14 type 1 diabetes, without ESM | Smartphone | Fixed signal-contingent & event-contingent | 30 days | 4 | NR | 64.17% | $60–$100 |
| Nap-van der Vlist (2021)31 | Illnesses associated with fatigue | No | Smartphone | Fixed signal-contingent | 10–67 days | 5 | <27 | 42% | NR |
| Psihogios et al. (2021)30 | Acute lymphoblastic leukaemia | No | Smartphone + wearable | Fixed signal-contingent & event-contingent | 28 days | 3–4 | 2–9 | 79.5%-88.9% | Dependent on compliance |
| Rancourt et al. (2015)49 | Obesity | No | Royal Brand PDA | Random signal-contingent | 5 days | 6 | 8 | NR | Study credits |
| Rofey et al. (2010)78 | Obesity | No | Phone calls + wearable | Random signal-contingent | NR | 2-4 | NR | 64.2% | NR |
| Schurman & Friesen (2015)50 | Chronic abdominal pain | No | Palm device | Fixed signal-contingent | 14 days | 3 | CD | 86% | NR |
| Shapira et al. (2020)58 | Type 1 diabetes | No | Palm Tungsten E2 | Fixed signal-contingent | 2 weeks | 4 | 12 | 72% (median) | NR |
| Smith et al. (2021)55 | Obesity | 39 non-obese siblings | Cell phone + wearable | Interval-contingent | 7 days | 4-7 | 5 | 95.0% | CD |
| Stinson et al. (2014)24 | Juvenile idiopathic arthritis | No | Palm Tungsten W PDA | Fixed signal-contingent | 14 days | 3 | CD | 78% | NR |
| Sweenie et al. (2022)37 | Asthma | No | Phone + wearable | Fixed signal-contingent | 21 days | 4 | 12 | 67.5% | $25 or $40 |
| Tasian et al. (2019)39 a | Nephrolithiasis | No | Phone | Random signal-contingent | 7 days | 4 | CD | 85% | NR |
| Teufel et al. (2018)29 | Asthma | No | Smartphone + wearable | Signal-contingent | 2 months | 1 | 8 | 20% | $50 or $200 |
| Valrie et al. (2019)34 | Sickle cell disease | No | Smartphone + wearable | Semi-fixed signal-contingent | 4 weeks | 2 | 6-10 | 81.87% | $20 or $60 |
| Warnick et al. (2020)79 | Type 1 diabetes | No | Smartphone | Fixed signal-contingent | 10 days | 3 | 4 | 43.80% | $10 |
| Zhang et al. (2022)15 | Type 1 diabetes | No | Smartphone + blood glucose meter | Fixed signal-contingent | 30 days | CD | CD | NR | NR |
aEstimated using the method described by Shi et al.23
CD Cannot determine, NR Not reported.